| Bioactivity | LH10 is a fexaramine-based agonist for FXR with an EC50 of 0.14 μM. LH10 exhibits liver protection efficacy, ameliorates the alpha naphthylisothiocyanate (ANIT)-induced cholestasis, APAP (HY-66005)-induced acute liver injury and non-alcoholic steatohepatitis (NASH) in mouse models[1]. |
| Target | EC50: FXR (0.14 μM) |
| Formula | C34H33N3O2 |
| Molar Mass | 515.64 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Huang W, et al., Discovery of LH10, a novel fexaramine-based FXR agonist for the treatment of liver disease. Bioorg Chem. 2024 Feb;143:107071. |